Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...

Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a CGM to market.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Almost 2.4 million Americans wear continuous glucose monitors, or CGMs, to track their blood sugar—and not all of them have ...

Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes.

The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...

Its innovative CGM systems, like the G6 and the newer G7 ... G7 system and further development of offerings like the Dexcom Stelo, targeting non-insulin-using diabetes patients.

DexCom (NasdaqGS:DXCM) recently received a warning letter from the FDA, which pointed out issues in manufacturing processes and quality management. While these regulatory developments did not impact ...

SAN DIEGO, August 26, 2024--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the ...

Rival Abbott launched its own OTC CGM, Lingo, weeks after Dexcom's Stelo debut. The company is counting on further international expansion to drive growth after it said it had improved access to ...